Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Role of hepatic PKCβ in nutritional regulation of hepatic glycogen synthesis
Yaoling Shu, … , Michael C. Ostrowski, Kamal D. Mehta
Yaoling Shu, … , Michael C. Ostrowski, Kamal D. Mehta
Published October 8, 2021
Citation Information: JCI Insight. 2021;6(19):e149023. https://doi.org/10.1172/jci.insight.149023.
View: Text | PDF
Research Article Hepatology

Role of hepatic PKCβ in nutritional regulation of hepatic glycogen synthesis

  • Text
  • PDF
Abstract

The signaling mechanisms by which dietary fat and cholesterol signals regulate central pathways of glucose homeostasis are not completely understood. By using a hepatocyte-specific PKCβ-deficient (PKCβHep–/–) mouse model, we demonstrated the role of hepatic PKCβ in slowing disposal of glucose overload by suppressing glycogenesis and increasing hepatic glucose output. PKCβHep–/– mice exhibited lower plasma glucose under the fed condition, modestly improved systemic glucose tolerance and mildly suppressed gluconeogenesis, increased hepatic glycogen accumulation and synthesis due to elevated glucokinase expression and activated glycogen synthase (GS), and suppressed glucose-6-phosphatase expression compared with controls. These events were independent of hepatic AKT/GSK-3α/β signaling and were accompanied by increased HNF-4α transactivation, reduced FoxO1 protein abundance, and elevated expression of GS targeting protein phosphatase 1 regulatory subunit 3C in the PKCβHep–/– liver compared with controls. The above data strongly imply that hepatic PKCβ deficiency causes hypoglycemia postprandially by promoting glucose phosphorylation via upregulating glucokinase and subsequently redirecting more glucose-6-phosphate to glycogen via activating GS. In summary, hepatic PKCβ has a unique and essential ability to induce a coordinated response that negatively affects glycogenesis at multiple levels under physiological postprandial conditions, thereby integrating nutritional fat intake with dysregulation of glucose homeostasis.

Authors

Yaoling Shu, Faizule Hassan, Michael C. Ostrowski, Kamal D. Mehta

×

Figure 2

Hepatic PKCβ deficiency promotes glycogen accumulation in the liver.

Options: View larger image (or click on image) Download as PowerPoint
Hepatic PKCβ deficiency promotes glycogen accumulation in the liver.
(A)...
(A) Comparison of G6P content in the liver of PKCβfl/fl and PKCβHep–/– mice fed HFHC diet for 12 weeks. (B) Glycogen content in liver and skeletal muscle (hind limb) under fed condition and in the liver after a 16-hour fast. (C) Representative PAS staining of liver from above HFHC-fed PKCβfl/fl and PKCβHep–/– mice. (D) 2-Deoxy-D-[3H] glucose incorporation into glycogen measured after 12–16 hours of fasting in PKCβfl/fl and PKCβHep–/– mice fed HFHC diet for 12 weeks. Label incorporation was measured as cpm from precipitated glycogen from liver tissue lysate and normalized to plasma cpm/mg protein. The results are mean ± SEM. n = 3–6 mice/genotype in each group. *P < 0.05 versus control mice by 2-tailed t tests (A and D) or 2-way ANOVA followed by Bonferroni’s multiple-comparison test (B). Total original magnification, ×200.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts